V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) antibody

Details for Product No. ABIN968991
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms B-RAF1, BRAF1, NS7, RAFB1, RMIL, C-RMIL, 9930012E13Rik, AA120551, AA387315, AA473386, B-raf, Braf-2, Braf2, C230098H17, C87398, D6Ertd631e, B-Raf, braf1, rafb1, b-raf1, sierrabraf, BRAF
Reactivity
Human, Mouse (Murine)
(177), (23), (20), (6), (4), (1), (1), (1), (1)
Host
Mouse
(110), (63), (4), (2)
Clonality (Clone)
Monoclonal ()
Conjugate
Un-conjugated
(3), (3), (3), (3), (3), (3), (3), (3), (3), (3), (3)
Application
ELISA, Western Blotting (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC)
(120), (75), (44), (44), (30), (20), (18), (10), (3), (2), (1), (1), (1)
Pubmed 2 references available
Catalog no. ABIN968991
Quantity 100 µL
Price
363.00 $   Plus shipping costs $45.00
Options
Shipping to United States (Change)
Availability Will be delivered in 3 to 4 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen Purified recombinant fragment of human BRAF expressed in E. coli.
Clone 1H12
Isotype IgG1
Purification Ascites
Alternative Name BRAF
Background Synonyms:
BRAF1, RAFB1, B-RAF1, FLJ95109
BRAF: v-raf murine sarcoma viral oncogene homolog B1, also known as BRAF1, RAFB1, B-RAF1, FLJ95109. Entrez Protein NP_004324. It is the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway. B-Raf contains three consensus Akt phosphorylationsites (Ser364, Ser428, and Thr439). B-Raf is a key regulatory molecule of the mitogen-activated protein kinase kinase (MEK), it has a long amino-terminal region,the region is essential for homo-dimerization of B-Raf and hetero-dimerization of B-Raf and c-Raf at the plasma membrane, followed by phosphorylation of Thr118 in the amino-terminal B-Raf-specific region. Notably, in calcium ionophore-stimulated HeLa cells, B-Raf could propagate signals to MEK under the basal level of GTP-Ras. Expression of Raf-B is highly restricted with highestlevels in the cerebrum and testes and defects in braf are involved in a wide range of cancers. The BRAF gene mutation is frequently detected in papillary thyroid carcinoma,melanocytic nevi, primary cutaneous melanomas and colorectal cancers.
Molecular Weight 87 kDa
Gene ID 673
Application Notes Recommended Dilution:
ELISA: 1/10000, WB: 1/500 - 1/2000, IHC: 1/200 - 1/1000, ICC: 1/200 - 1/1000
Not yet tested in other applications.
Determining optimal working dilutions by titration test.
Restrictions For Research Use only
Format Liquid
Buffer Ascitic fluid containing 0.03 % sodium azide.
Preservative Sodium azide
Storage 4 °C/-20 °C
Storage Comment Store at 4 °C or at -20 °C for long term.
Supplier Images
anti-V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) antibody Figure 3: Confocal immunofluorescence analysis of MCF-7 (left) and HepG2 (right) cells using BRAF mouse mAb (green) . Red: Actin filaments have been labeled with DY-554 phalloidin. Blue: DRAQ5 fluorescent DNA dye
anti-V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) antibody (2) Figure 2: Immunohistochemical analysis of paraffin-embedded human testis tissues using BRAF mouse mAb.
anti-V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) antibody (3) Figure 1: Western blot analysis using BRAF mouse mAb against Hela (1), HL60 (2), HepG2 (3) and NIH/3T3 (4) cell lysate.
Product cited in: Riesco-Eizaguirre, Gutiérrez-Martínez, García-Cabezas et al.: "The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane." in: Endocrine-related cancer, Vol. 13, Issue 1, pp. 257-69, 2006 (PubMed).

Di Nicolantonio, Martini, Molinari et al.: "Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 26, Issue 35, pp. 5705-12, 2008 (PubMed).

Hosts (110), (63), (4), (2)
Reactivities (177), (23), (20), (6), (4), (1), (1), (1), (1)
Applications (120), (75), (44), (44), (30), (20), (18), (10), (3), (2), (1), (1), (1)
Conjugates (3), (3), (3), (3), (3), (3), (3), (3), (3), (3), (3)
Epitopes (17), (16), (13), (12), (9), (6), (4), (4), (4), (3), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
back to top